HDAC9 and cancer: To determine if normal cells also showed a differential response to HDAC inhibitors and to measure the selectivity of these drugs for cancer cells vs normal cells, we performed cell viability assays on a series of immortalised human bronchial epithelial cells (HBECs) that are non-tumourigenic (Ramirez et al, 2004; Sato et al, 2006).